Francesco Carletti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Francesco Carletti has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Philip McGuire
University of Oxford
9 shared publications - Paolo Fusar-Poli
Early Psychosis: Interventions and Clinical-detection (EPIC) lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
6 shared publications - Elvira Bramon
Division of Psychiatry, Department of Mental Health Neuroscience, University College London, London, UK
4 shared publications - Matthew R. Broome
Uehiro Oxford Institute, University of Oxford, Oxford, UK; School of Psychology, University of Birmingham, Birmingham, UK
4 shared publications - Gareth J. Barker
Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
3 shared publications Hans Rolf Jäger
Department of Radiology, University College London Hospitals NHS Foundation Trust , London , United Kingdom
3 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9878
Spatiotemporal characterization of Alzheimer disease pathology in living human brain tissue
Alzheimer disease begins in the brain many years before symptoms, but early changes are usually studied after death or indirectly through fluid and imaging biomarkers. Here we show that small brain biopsies collected during ventriculoperitoneal shunt surgery can be used to study Alzheimer disease pathology and protein turnover during life. We analysed biopsies from 18 individuals with suspected normal pressure hydrocephalus, alongside matched ventricular and lumbar cerebrospinal fluid and post-mortem control brain tissue. Amyloid plaques were present in 9 of 18 biopsies, while mature tau tangles were rare. Matrix-assisted laser desorption/ionization mass spectrometry imaging mapped amyloid plaque chemistry within tissue. Phosphorylated tau 217 was enriched around plaques, supporting a local relationship between amyloid and tau pathology. Stable isotope labelling, which tracks newly made proteins, detected rapid tau labelling within approximately 3 hours and estimated brain tau half-life at about 34 days. Amyloid plaques showed little detectable turnover.
- 24 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9878
Open AccessSpatiotemporal characterization of Alzheimer disease pathology in living human brain tissue
Alzheimer disease begins in the brain many years before symptoms, but early changes are usually studied after death or indirectly through fluid and imaging biomarkers. Here we show that small brain biopsies collected during ventriculoperitoneal shunt surgery can be used to study Alzheimer disease pathology and protein turnover during life. We analysed biopsies from 18 individuals with suspected normal pressure hydrocephalus, alongside matched ventricular and lumbar cerebrospinal fluid and post-mortem control brain tissue. Amyloid plaques were present in 9 of 18 biopsies, while mature tau tangles were rare. Matrix-assisted laser desorption/ionization mass spectrometry imaging mapped amyloid plaque chemistry within tissue. Phosphorylated tau 217 was enriched around plaques, supporting a local relationship between amyloid and tau pathology. Stable isotope labelling, which tracks newly made proteins, detected rapid tau labelling within approximately 3 hours and estimated brain tau half-life at about 34 days. Amyloid plaques showed little detectable turnover.
- Open Access
- 28 October 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 457-460
Adult Cerebral Malaria: Acute and Subacute Imaging Findings, Long-term Clinical Consequences
Cerebral malaria is an important cause of mortality and neurodisability in endemic regions. We show magnetic resonance imaging (MRI) features suggestive of cytotoxic and vasogenic cerebral edema followed by microhemorrhages in 2 adult UK cases, comparing them with an Indian cohort. Long-term follow-up images correlate ongoing changes with residual functional impairment.
- 28 October 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 457-460
Open AccessAdult Cerebral Malaria: Acute and Subacute Imaging Findings, Long-term Clinical Consequences
Cerebral malaria is an important cause of mortality and neurodisability in endemic regions. We show magnetic resonance imaging (MRI) features suggestive of cytotoxic and vasogenic cerebral edema followed by microhemorrhages in 2 adult UK cases, comparing them with an Indian cohort. Long-term follow-up images correlate ongoing changes with residual functional impairment.
- Open Access
- 12 May 2021
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 3 (3) , fcab099
Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes
Preliminary pathological and biomarker data suggest that SARS-CoV-2 infection can damage the nervous system. To understand what, where and how damage occurs, we collected serum and CSF from patients with COVID-19 and characterized neurological syndromes involving the PNS and CNS (n = 34). We measured biomarkers of neuronal damage and neuroinflammation, and compared these with non-neurological control groups, which included patients with (n = 94) and without (n = 24) COVID-19. We detected increased concentrations of neurofilament light, a dynamic biomarker of neuronal damage, in the CSF of those with CNS inflammation (encephalitis and acute disseminated encephalomyelitis) [14 800 pg/ml (400, 32 400)], compared to those with encephalopathy [1410 pg/ml (756, 1446)], peripheral syndromes (Guillain–Barré syndrome) [740 pg/ml (507, 881)] and controls [872 pg/ml (654, 1200)]. Serum neurofilament light levels were elevated across patients hospitalized with COVID-19, irrespective of neurological manifestations. There was not the usual close correlation between CSF and serum neurofilament light, suggesting serum neurofilament light elevation in the non-neurological patients may reflect peripheral nerve damage in response to severe illness. We did not find significantly elevated levels of serum neurofilament light in community cases of COVID-19 arguing against significant neurological damage. Glial fibrillary acidic protein, a marker of astrocytic activation, was not elevated in the CSF or serum of any group, suggesting astrocytic activation is not a major mediator of neuronal damage in COVID-19.
- 12 May 2021
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 3 (3) , fcab099
Open AccessSerum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes
Preliminary pathological and biomarker data suggest that SARS-CoV-2 infection can damage the nervous system. To understand what, where and how damage occurs, we collected serum and CSF from patients with COVID-19 and characterized neurological syndromes involving the PNS and CNS (n = 34). We measured biomarkers of neuronal damage and neuroinflammation, and compared these with non-neurological control groups, which included patients with (n = 94) and without (n = 24) COVID-19. We detected increased concentrations of neurofilament light, a dynamic biomarker of neuronal damage, in the CSF of those with CNS inflammation (encephalitis and acute disseminated encephalomyelitis) [14 800 pg/ml (400, 32 400)], compared to those with encephalopathy [1410 pg/ml (756, 1446)], peripheral syndromes (Guillain–Barré syndrome) [740 pg/ml (507, 881)] and controls [872 pg/ml (654, 1200)]. Serum neurofilament light levels were elevated across patients hospitalized with COVID-19, irrespective of neurological manifestations. There was not the usual close correlation between CSF and serum neurofilament light, suggesting serum neurofilament light elevation in the non-neurological patients may reflect peripheral nerve damage in response to severe illness. We did not find significantly elevated levels of serum neurofilament light in community cases of COVID-19 arguing against significant neurological damage. Glial fibrillary acidic protein, a marker of astrocytic activation, was not elevated in the CSF or serum of any group, suggesting astrocytic activation is not a major mediator of neuronal damage in COVID-19.
- Top Cited PapersOpen Access
- 8 July 2020
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (10) , 3104-3120
The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings
Preliminary clinical data indicate that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with neurological and neuropsychiatric illness. Responding to this, a weekly virtual coronavirus disease 19 (COVID-19) neurology multi-disciplinary meeting was established at the National Hospital, Queen Square, in early March 2020 in order to discuss and begin to understand neurological presentations in patients with suspected COVID-19-related neurological disorders. Detailed clinical and paraclinical data were collected from cases where the diagnosis of COVID-19 was confirmed through RNA PCR, or where the diagnosis was probable/possible according to World Health Organization criteria. Of 43 patients, 29 were SARS-CoV-2 PCR positive and definite, eight probable and six possible. Five major categories emerged: (i) encephalopathies (n = 10) with delirium/psychosis and no distinct MRI or CSF abnormalities, and with 9/10 making a full or partial recovery with supportive care only; (ii) inflammatory CNS syndromes (n = 12) including encephalitis (n = 2, para- or post-infectious), acute disseminated encephalomyelitis (n = 9), with haemorrhage in five, necrosis in one, and myelitis in two, and isolated myelitis (n = 1). Of these, 10 were treated with corticosteroids, and three of these patients also received intravenous immunoglobulin; one made a full recovery, 10 of 12 made a partial recovery, and one patient died; (iii) ischaemic strokes (n = 8) associated with a pro-thrombotic state (four with pulmonary thromboembolism), one of whom died; (iv) peripheral neurological disorders (n = 8), seven with Guillain-Barré syndrome, one with brachial plexopathy, six of eight making a partial and ongoing recovery; and (v) five patients with miscellaneous central disorders who did not fit these categories. SARS-CoV-2 infection is associated with a wide spectrum of neurological syndromes affecting the whole neuraxis, including the cerebral vasculature and, in some cases, responding to immunotherapies. The high incidence of acute disseminated encephalomyelitis, particularly with haemorrhagic change, is striking. This complication was not related to the severity of the respiratory COVID-19 disease. Early recognition, investigation and management of COVID-19-related neurological disease is challenging. Further clinical, neuroradiological, biomarker and neuropathological studies are essential to determine the underlying pathobiological mechanisms, which will guide treatment. Longitudinal follow-up studies will be necessary to ascertain the long-term neurological and neuropsychological consequences of this pandemic.
- 8 July 2020
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (10) , 3104-3120
Top Cited PapersOpen AccessThe emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings
Preliminary clinical data indicate that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with neurological and neuropsychiatric illness. Responding to this, a weekly virtual coronavirus disease 19 (COVID-19) neurology multi-disciplinary meeting was established at the National Hospital, Queen Square, in early March 2020 in order to discuss and begin to understand neurological presentations in patients with suspected COVID-19-related neurological disorders. Detailed clinical and paraclinical data were collected from cases where the diagnosis of COVID-19 was confirmed through RNA PCR, or where the diagnosis was probable/possible according to World Health Organization criteria. Of 43 patients, 29 were SARS-CoV-2 PCR positive and definite, eight probable and six possible. Five major categories emerged: (i) encephalopathies (n = 10) with delirium/psychosis and no distinct MRI or CSF abnormalities, and with 9/10 making a full or partial recovery with supportive care only; (ii) inflammatory CNS syndromes (n = 12) including encephalitis (n = 2, para- or post-infectious), acute disseminated encephalomyelitis (n = 9), with haemorrhage in five, necrosis in one, and myelitis in two, and isolated myelitis (n = 1). Of these, 10 were treated with corticosteroids, and three of these patients also received intravenous immunoglobulin; one made a full recovery, 10 of 12 made a partial recovery, and one patient died; (iii) ischaemic strokes (n = 8) associated with a pro-thrombotic state (four with pulmonary thromboembolism), one of whom died; (iv) peripheral neurological disorders (n = 8), seven with Guillain-Barré syndrome, one with brachial plexopathy, six of eight making a partial and ongoing recovery; and (v) five patients with miscellaneous central disorders who did not fit these categories. SARS-CoV-2 infection is associated with a wide spectrum of neurological syndromes affecting the whole neuraxis, including the cerebral vasculature and, in some cases, responding to immunotherapies. The high incidence of acute disseminated encephalomyelitis, particularly with haemorrhagic change, is striking. This complication was not related to the severity of the respiratory COVID-19 disease. Early recognition, investigation and management of COVID-19-related neurological disease is challenging. Further clinical, neuroradiological, biomarker and neuropathological studies are essential to determine the underlying pathobiological mechanisms, which will guide treatment. Longitudinal follow-up studies will be necessary to ascertain the long-term neurological and neuropsychological consequences of this pandemic.
- Open Access
- 1 April 2018
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 44 (suppl_1) , S50-S51
31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS
The response to antipsychotic treatment in patients with psychosis is difficult to predict on the basis of the patient’s clinical features. As a result, patients are generally treated in a similar way, even though their response can vary dramatically. Recent neuroimaging studies suggest that the pattern of brain abnormalities in patients with psychosis may vary in relation to treatment response. However, in many of these studies, patients had already been treated, and it was unclear if this had contributed to the findings. In Optimise we obtained a structural Magnetic Resonance Imaging data from n=203 minimally treated patients at their first presentation for a psychotic episode. All patients then started treatment with standard doses of amisulpride. After 4 weeks, 56% were in symptomatic remission. We identified brain neoplasms in 3 patients, but the most common radiological findings were non-specific white matter T2-weighted hyperintensities (n=48); cavum septi pelludici (n=34); and arachnoid cysts (n=9). Cortical thickness, surface area, and gyrification were measured using Freesurfer (). Preliminary analyses applying machine learning to these measures at baseline indicated that symptomatic remission at 4 weeks could be predicted with an accuracy of 64%. These findings suggest that radiological assessment can identify abnormalties that require an alternative to conventional treatment in a minority of patients. In most patients with psychosis, neuroimaging abnormalities may be better detected using statistical approaches, and these have greater potential for the stratification of patients according to future antipsychotic response.
- 1 April 2018
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 44 (suppl_1) , S50-S51
Open Access31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS
The response to antipsychotic treatment in patients with psychosis is difficult to predict on the basis of the patient’s clinical features. As a result, patients are generally treated in a similar way, even though their response can vary dramatically. Recent neuroimaging studies suggest that the pattern of brain abnormalities in patients with psychosis may vary in relation to treatment response. However, in many of these studies, patients had already been treated, and it was unclear if this had contributed to the findings. In Optimise we obtained a structural Magnetic Resonance Imaging data from n=203 minimally treated patients at their first presentation for a psychotic episode. All patients then started treatment with standard doses of amisulpride. After 4 weeks, 56% were in symptomatic remission. We identified brain neoplasms in 3 patients, but the most common radiological findings were non-specific white matter T2-weighted hyperintensities (n=48); cavum septi pelludici (n=34); and arachnoid cysts (n=9). Cortical thickness, surface area, and gyrification were measured using Freesurfer (). Preliminary analyses applying machine learning to these measures at baseline indicated that symptomatic remission at 4 weeks could be predicted with an accuracy of 64%. These findings suggest that radiological assessment can identify abnormalties that require an alternative to conventional treatment in a minority of patients. In most patients with psychosis, neuroimaging abnormalities may be better detected using statistical approaches, and these have greater potential for the stratification of patients according to future antipsychotic response.
- 1 February 2015
- Published by Elsevier in Schizophrenia Research
- Vol. 161 (2-3) , 277-282
Sensory gating deficits in the attenuated psychosis syndrome
- 1 February 2015
- Published by Elsevier in Schizophrenia Research
- Vol. 161 (2-3) , 277-282
Sensory gating deficits in the attenuated psychosis syndrome
- Top Cited PapersOpen Access
- 19 June 2014
- Published by Oxford University Press (OUP) in Brain
- Vol. 137 (8) , 2382-2395
The hubs of the human connectome are generally implicated in the anatomy of brain disorders
Brain networks or ‘connectomes’ include a minority of highly connected hub nodes that are functionally valuable, because their topological centrality supports integrative processing and adaptive behaviours. Recent studies also suggest that hubs have higher metabolic demands and longer-distance connections than other brain regions, and therefore could be considered biologically costly. Assuming that hubs thus normally combine both high topological value and high biological cost, we predicted that pathological brain lesions would be concentrated in hub regions. To test this general hypothesis, we first identified the hubs of brain anatomical networks estimated from diffusion tensor imaging data on healthy volunteers (n = 56), and showed that computational attacks targeted on hubs disproportionally degraded the efficiency of brain networks compared to random attacks. We then prepared grey matter lesion maps, based on meta-analyses of published magnetic resonance imaging data on more than 20 000 subjects and 26 different brain disorders. Magnetic resonance imaging lesions that were common across all brain disorders were more likely to be located in hubs of the normal brain connectome (P < 10−4, permutation test). Specifically, nine brain disorders had lesions that were significantly more likely to be located in hubs (P < 0.05, permutation test), including schizophrenia and Alzheimer’s disease. Both these disorders had significantly hub-concentrated lesion distributions, although (almost completely) distinct subsets of cortical hubs were lesioned in each disorder: temporal lobe hubs specifically were associated with higher lesion probability in Alzheimer’s disease, whereas in schizophrenia lesions were concentrated in both frontal and temporal cortical hubs. These results linking pathological lesions to the topological centrality of nodes in the normal diffusion tensor imaging connectome were generally replicated when hubs were defined instead by the meta-analysis of more than 1500 task-related functional neuroimaging studies of healthy volunteers to create a normative functional co-activation network. We conclude that the high cost/high value hubs of human brain networks are more likely to be anatomically abnormal than non-hubs in many (if not all) brain disorders.
- 19 June 2014
- Published by Oxford University Press (OUP) in Brain
- Vol. 137 (8) , 2382-2395
Top Cited PapersOpen AccessThe hubs of the human connectome are generally implicated in the anatomy of brain disorders
Brain networks or ‘connectomes’ include a minority of highly connected hub nodes that are functionally valuable, because their topological centrality supports integrative processing and adaptive behaviours. Recent studies also suggest that hubs have higher metabolic demands and longer-distance connections than other brain regions, and therefore could be considered biologically costly. Assuming that hubs thus normally combine both high topological value and high biological cost, we predicted that pathological brain lesions would be concentrated in hub regions. To test this general hypothesis, we first identified the hubs of brain anatomical networks estimated from diffusion tensor imaging data on healthy volunteers (n = 56), and showed that computational attacks targeted on hubs disproportionally degraded the efficiency of brain networks compared to random attacks. We then prepared grey matter lesion maps, based on meta-analyses of published magnetic resonance imaging data on more than 20 000 subjects and 26 different brain disorders. Magnetic resonance imaging lesions that were common across all brain disorders were more likely to be located in hubs of the normal brain connectome (P < 10−4, permutation test). Specifically, nine brain disorders had lesions that were significantly more likely to be located in hubs (P < 0.05, permutation test), including schizophrenia and Alzheimer’s disease. Both these disorders had significantly hub-concentrated lesion distributions, although (almost completely) distinct subsets of cortical hubs were lesioned in each disorder: temporal lobe hubs specifically were associated with higher lesion probability in Alzheimer’s disease, whereas in schizophrenia lesions were concentrated in both frontal and temporal cortical hubs. These results linking pathological lesions to the topological centrality of nodes in the normal diffusion tensor imaging connectome were generally replicated when hubs were defined instead by the meta-analysis of more than 1500 task-related functional neuroimaging studies of healthy volunteers to create a normative functional co-activation network. We conclude that the high cost/high value hubs of human brain networks are more likely to be anatomically abnormal than non-hubs in many (if not all) brain disorders.
- 1 February 2013
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 48 (2) , 104-112
Feasibility of Diffusion Tensor Tractography of Brachial Plexus Injuries at 1.5 T
Objective The objective of this study was to examine the feasibility of diffusion tensor imaging and diffusion tensor tractography (DTT) at 1.5 T for the detection of nerve root avulsions in patients with brachial plexus injuries (BPI). Materials and Methods We performed a 1.5-T magnetic resonance imaging on 28 patients (mean [SD] age, 25 [9.1]) with BPI using the following imaging protocol: (a) magnetic resonance myelography (MRM), (b) magnetic resonance neurography, and (c) diffusion tensor imaging. A reproducible tractography approach was developed to assess the myeloradicular continuity, which consists of multiple regions of interests placed on each hemicord, including the ventral and dorsal rootlets from C4 to T2 nerve roots. Two independent observers blindly evaluated DTT and MRM studies. The degree of agreement between DTT and MRM findings was estimated on a per-root basis on the 140 nerve roots (C5-T1) on the injured side by calculation of the κ coefficient (K value) and the Bland-Altman plot analysis. The diagnostic accuracy of DTT was assessed by comparing it with the MRM findings of the 140 nerve roots on the injured side on a per-root basis. Results Diffusion tensor tractography allowed a complete visualization of the C5-T1 intact nerve roots on the normal side in 100% of studies. Complete nerve root avulsions were recognized on DTT either as a total loss of fibers or as a very short segment of incoherent fibers in apparent continuity with the spinal cord. The MRM identified 88 intact nerve roots (62.9%), 44 completely avulsed nerve roots (31.4%), and 8 partially avulsed nerve roots (5.7%). The DTT and MRM were concordant in 127 of the 140 nerve roots (90.7%) and exhibited an excellent overall agreement (K value, 80.8). The brachial plexus DTT had an 88.1% sensitivity, 98.1% positive predictive value, 98.8% specificity, 92.6 negative predictive value, and a 94.5% overall accuracy for detecting the presence of a nerve root avulsion. The κ coefficients for the interobserver reliability of DTT and MRM were 0.85 and 0.80, respectively. Conclusions Our results suggest that cervical nerve root avulsions can be successfully visualized at 1.5 T in patients with BPI despite the anatomical complexity and susceptibility and motion artifacts. We propose that DTT is a reliable and reproducible method for the investigation of BPI because it provides a successful anatomical and functional display of neural structures that are not otherwise attainable with conventional studies.
- 1 February 2013
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 48 (2) , 104-112
Feasibility of Diffusion Tensor Tractography of Brachial Plexus Injuries at 1.5 T
Objective The objective of this study was to examine the feasibility of diffusion tensor imaging and diffusion tensor tractography (DTT) at 1.5 T for the detection of nerve root avulsions in patients with brachial plexus injuries (BPI). Materials and Methods We performed a 1.5-T magnetic resonance imaging on 28 patients (mean [SD] age, 25 [9.1]) with BPI using the following imaging protocol: (a) magnetic resonance myelography (MRM), (b) magnetic resonance neurography, and (c) diffusion tensor imaging. A reproducible tractography approach was developed to assess the myeloradicular continuity, which consists of multiple regions of interests placed on each hemicord, including the ventral and dorsal rootlets from C4 to T2 nerve roots. Two independent observers blindly evaluated DTT and MRM studies. The degree of agreement between DTT and MRM findings was estimated on a per-root basis on the 140 nerve roots (C5-T1) on the injured side by calculation of the κ coefficient (K value) and the Bland-Altman plot analysis. The diagnostic accuracy of DTT was assessed by comparing it with the MRM findings of the 140 nerve roots on the injured side on a per-root basis. Results Diffusion tensor tractography allowed a complete visualization of the C5-T1 intact nerve roots on the normal side in 100% of studies. Complete nerve root avulsions were recognized on DTT either as a total loss of fibers or as a very short segment of incoherent fibers in apparent continuity with the spinal cord. The MRM identified 88 intact nerve roots (62.9%), 44 completely avulsed nerve roots (31.4%), and 8 partially avulsed nerve roots (5.7%). The DTT and MRM were concordant in 127 of the 140 nerve roots (90.7%) and exhibited an excellent overall agreement (K value, 80.8). The brachial plexus DTT had an 88.1% sensitivity, 98.1% positive predictive value, 98.8% specificity, 92.6 negative predictive value, and a 94.5% overall accuracy for detecting the presence of a nerve root avulsion. The κ coefficients for the interobserver reliability of DTT and MRM were 0.85 and 0.80, respectively. Conclusions Our results suggest that cervical nerve root avulsions can be successfully visualized at 1.5 T in patients with BPI despite the anatomical complexity and susceptibility and motion artifacts. We propose that DTT is a reliable and reproducible method for the investigation of BPI because it provides a successful anatomical and functional display of neural structures that are not otherwise attainable with conventional studies.
- Open Access
- 3 April 2012
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 38 (6) , 1170-1179
Alterations in White Matter Evident Before the Onset of Psychosis
Psychotic disorders are associated with widespread reductions in white matter (WM) integrity. However, the stage at which these abnormalities first appear and whether they are correlates of psychotic illness, as opposed to an increased vulnerability to psychosis, is unclear. We addressed these issues by using diffusion tensor imaging (DTI) to study subjects at ultra high risk (UHR) of psychosis before and after the onset of illness. Thirty-two individuals at UHR for psychosis, 32 controls, and 15 patients with first-episode schizophrenia were studied using DTI. The UHR subjects and controls were re-scanned after 28 months. During this period, 8 UHR subjects had developed schizophrenia. Between-group differences in fractional anisotropy (FA) and diffusivity were evaluated cross sectionally and longitudinally using a nonparametric voxel-based analysis. At baseline, WM DTI properties were significantly different between the 3 groups (P < .001). Relative to controls, first-episode patients showed widespread reductions in FA and increases in diffusivity. DTI indices in the UHR group were intermediate relative to those in the other 2 groups. Longitudinal analysis revealed a significant group by time interaction in the left frontal WM (P < .001). In this region, there was a progressive reduction in FA in UHR subjects who developed psychosis that was not evident in UHR subjects who did not make a transition. People at UHR for psychosis show alterations in WM qualitatively similar to, but less severe than, those in patients with schizophrenia. The onset of schizophrenia may be associated with a progressive reduction in the integrity of the frontal WM.
- 3 April 2012
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 38 (6) , 1170-1179
Open AccessAlterations in White Matter Evident Before the Onset of Psychosis
Psychotic disorders are associated with widespread reductions in white matter (WM) integrity. However, the stage at which these abnormalities first appear and whether they are correlates of psychotic illness, as opposed to an increased vulnerability to psychosis, is unclear. We addressed these issues by using diffusion tensor imaging (DTI) to study subjects at ultra high risk (UHR) of psychosis before and after the onset of illness. Thirty-two individuals at UHR for psychosis, 32 controls, and 15 patients with first-episode schizophrenia were studied using DTI. The UHR subjects and controls were re-scanned after 28 months. During this period, 8 UHR subjects had developed schizophrenia. Between-group differences in fractional anisotropy (FA) and diffusivity were evaluated cross sectionally and longitudinally using a nonparametric voxel-based analysis. At baseline, WM DTI properties were significantly different between the 3 groups (P < .001). Relative to controls, first-episode patients showed widespread reductions in FA and increases in diffusivity. DTI indices in the UHR group were intermediate relative to those in the other 2 groups. Longitudinal analysis revealed a significant group by time interaction in the left frontal WM (P < .001). In this region, there was a progressive reduction in FA in UHR subjects who developed psychosis that was not evident in UHR subjects who did not make a transition. People at UHR for psychosis show alterations in WM qualitatively similar to, but less severe than, those in patients with schizophrenia. The onset of schizophrenia may be associated with a progressive reduction in the integrity of the frontal WM.
- 1 April 2012
- Published by Elsevier in Schizophrenia Research
- Vol. 136, S201-S202
Poster #45 WHITE MATTER AND GENETIC RISK FOR SCHIZOPHRENIA: A TWIN DTI STUDY
- 1 April 2012
- Published by Elsevier in Schizophrenia Research
- Vol. 136, S201-S202
Poster #45 WHITE MATTER AND GENETIC RISK FOR SCHIZOPHRENIA: A TWIN DTI STUDY